SGLT2 Inhibitors: A Future in Cardiorenal Metabolic Syndrome

Join Drs Nihar Desai and Jay Udell as they discuss the role of SGLT2 inhibitors in the treatment of cardiorenal metabolic syndrome.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999841. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function https://pubmed.ncbi.nlm.nih.gov/33197224/

Study to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction - EMPACT-MI https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/04/05/03/00/empact-mi

The Bark Giving Diabetes Therapy Some Bite: The SGLT Inhibitors https://pubmed.ncbi.nlm.nih.gov/30132029/

Effects of Dapagliflozin on Development and Progression of Kidney Disease in Patients With Type 2 Diabetes: An Analysis From the DECLARE-TIMI 58 Randomized Trial https://pubmed.ncbi.nlm.nih.gov/31196815/

Thiazolidinediones and Heart Failure: A Teleo-Analysis https://pubmed.ncbi.nlm.nih.gov/17536074/

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/26378978/

Sotagliflozin in Patients With Diabetes and Recent Worsening Heart Failure https://pubmed.ncbi.nlm.nih.gov/33200892/

Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial https://pubmed.ncbi.nlm.nih.gov/38581389/

Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients https://pubmed.ncbi.nlm.nih.gov/10639539/